selected publications
-
academic article
-
Tate MHiggins GCDe Blasio MJLindblom RPrakoso DDeo MKiriazis HPark MBaeza-Garza CDCaldwell STHartley RCKrieg TMurphy MPCoughlan MTRitchie RH. Correction to: The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart.
Cardiovascular Drugs and Therapy.
34:223-223.
2020
Full text if available -
Perera NRitchie RHTate M. The Role of Bone Morphogenetic Proteins in Diabetic Complications.
ACS Pharmacology & Translational Science.
3:11-20.
2020
Full text if available -
Fu TMohan MBrennan EPWoodman OLGodson CKantharidis PRitchie RHQin CX. Therapeutic Potential of Lipoxin A4 in Chronic Inflammation: Focus on Cardiometabolic Disease.
ACS Pharmacology & Translational Science.
3:43-55.
2020
Full text if available -
Ritchie RDale Abel E. Basic mechanisms of diabetic heart disease.
Circulation Research.
126:1501-1525.
2020
Full text if available -
De Blasio MJHuynh NDeo MDubrana LEWalsh JWillis APrakoso DKiriazis HDonner DGChatham JCRitchie R. Defining the progression of diabetic cardiomyopathy in a mouse model of type 1 diabetes.
Frontiers in Physiology.
11:1-16.
2020
Full text if available -
Prakoso DDe Blasio MJTate MKiriazis HDonner DGQian HNash DDeo MWeeks KLParry LJGregorevic PMcMullen JRRitchie RH. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes.
American Journal of Physiology: Heart and Circulatory Physiology.
318:H840-H852.
2020
Full text if available -
Qin CXAnthonisz JLeo CHKahlberg NVelagic ALi MJap EWoodman OLParry LJHorowitz JDKemp-Harper BKRitchie RH. Nitric Oxide Resistance, Induced in the Myocardium by Diabetes, Is Circumvented by the Nitric Oxide Redox Sibling, Nitroxyl.
Antioxidants and Redox Signaling.
32:60-77.
2020
Full text if available -
Velagic AQin CWoodman OLHorowitz JDRitchie RKemp-Harper BK. Nitroxyl: a novel strategy to circumvent diabetes associated Impairments in nitric oxide signaling.
Frontiers in Pharmacology.
11:1-18.
2020
Full text if available -
Leo CHNg HHMarshall SAJelinic MRupasinghe TQin CRoessner URitchie RHTare MParry LJ. Relaxin reduces endothelium‐derived vasoconstriction in hypertension: Revealing new therapeutic insights.
British Journal of Pharmacology.
177:217-233.
2020
Full text if available -
Ritchie RGalougahi KKFigtree GA. Targeting longevity genes in the battle against diabetic heart disease – is there a gene delivery fountain of youth?.
European Journal of Heart Failure.
2020
Full text if available -
Marshall SAQin CXJelinic MO’sullivan KDeo MWalsh JLi MParry LJRitchie RHLeo CH. The novel small-molecule annexin-a1 mimetic, compound 17b, elicits vasoprotective actions in streptozotocin-induced diabetic mice.
International Journal of Molecular Sciences.
21.
2020
Full text if available -
Ramalingam ABudin SBFauzi NMRitchie RHZainalabidin S. Angiotensin II type I receptor antagonism attenuates nicotine-induced cardiac remodeling, dysfunction, and aggravation of myocardial ischemia-reperfusion injury in rats.
Frontiers in Pharmacology.
10.
2019
Full text if available -
Jelinic MKahlberg NLeo CHNg HHRosli SDeo MLi MFinlayson SWalsh JParry LJRitchie RHQin CX. Annexin-A1 deficiency exacerbates pathological remodelling of the mesenteric vasculature in insulin-resistance but not insulin-deficiency..
British Journal of Pharmacology.
177.
2019
Full text if available -
Qin CXRosli SDeo MCao NWalsh JTate MAlexander AEDonner DHorlock DLi RKiriazis HLee MKSBourke JEYang YMurphy AJDu X-JGao XMRitchie RH. Cardioprotective Actions of the Annexin-A1 N-Terminal Peptide, Ac2-26, Against Myocardial Infarction.
Frontiers in Pharmacology.
10.
2019
Full text if available -
Tate MPrakoso DWillis AMPeng CDeo MQin CXWalsh JLNash DMCohen CDRofe AKSharma AKiriazis HDonner DGde Haan JBWatson AMDDe Blasio MJRitchie RH. Characterising an alternative murine model of diabetic cardiomyopathy.
Frontiers in Physiology.
10.
2019
Full text if available -
Bubb KJRitchie RHFigtree GA. Modified redox signaling in vasculature after chronic infusion of the insulin receptor antagonist, S961.
Microcirculation.
26.
2019
Full text if available -
Senchenkova EYAnsari JBecker FVital SAAl-Yafeai ZSparkenbaugh EMPawlinski RStokes KYCarroll JLDragoi AMQin CXRitchie RHSun HCuellar-Saenz HHRubinstein MRHan YWOrr AWPerretti MGranger DNGavins FNE. Novel Role for the AnxA1-Fpr2/ALX signaling axis as a key regulator of platelet function to promote resolution of inflammation.
Circulation.
140:319-335.
2019
Full text if available -
Deora GSQin CXVecchio EADebono AJPriebbenow DLBrady RMBeveridge JTeguh SCDeo MMay LTKrippner GRitchie RHBaell JB. Substituted Pyridazin-3(2H)-ones as Highly Potent and Biased Formyl Peptide Receptor Agonists.
Journal of Medicinal Chemistry.
62:5242-5248.
2019
Full text if available -
Tate MHiggins GCDe Blasio MJLindblom RPrakoso DDeo MKiriazis HPark MBaeza-Garza CDCaldwell STHartley RCKrieg TMurphy MPCoughlan MTRitchie RH. The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart.
Cardiovascular Drugs and Therapy.
33:669-674.
2019
Full text if available -
Qin CXMay LTSexton PMDeBono AJBaell JBChristopoulos ARitchie RH. Correspondence: Reply to ‘Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury’.
Nature Communications.
9.
2018
Full text if available -
Chandramouli CReichelt MECurl CLVarma UBienvenu LAKoutsifeli PRaaijmakers AJADe Blasio MJQin CXJenkins AJRitchie RHMellor KMDelbridge LMD. Diastolic dysfunction is more apparent in STZ-induced diabetic female mice, despite less pronounced hyperglycemia.
Scientific Reports.
8.
2018
Full text if available -
Wanrooy BJKumar KPWen SWQin CXRitchie RHWong CHY. Distinct contributions of hyperglycemia and high-fat feeding in metabolic syndrome-induced neuroinflammation.
Journal of Neuroinflammation.
15.
2018
Full text if available -
Bernardo BCGregorevic PRitchie RHMcMullen JR. Generation of MicroRNA-34 sponges and tough decoys for the heart: Developments and challenges.
Frontiers in Pharmacology.
9.
2018
Full text if available -
Marwick THRitchie RShaw JEKaye D. Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy.
Journal of the American College of Cardiology.
71:339-351.
2018
Full text if available -
Sharma ATate MMathew GVince JERitchie RHde Haan JB. Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications.
Frontiers in Physiology.
9:1-15.
2018
Full text if available -
Ng HHLeo CHParry LJRitchie RH. Relaxin as a therapeutic target for the cardiovascular complications of diabetes.
Frontiers in Pharmacology.
9.
2018
Full text if available -
Spallotta FCencioni CAtlante SGarella DCocco MMori MMastrocola RKuenne CGuenther SNanni SAzzimato VZukunft SKornberger ASürün DSchnütgen FVon Melchner HDi Stilo AAragno MBraspenning MVan Criekinge WDe Blasio MJRitchie RHZaccagnini GMartelli FFarsetti AFleming IBraun TBeiras-Fernandez ABotta BCollino MBertinaria MZeiher AMGaetano C. Stable oxidative cytosine modifications accumulate in cardiac mesenchymal cells from type 2 diabetes patients: Rescue by α-ketoglutarate and TET-TDG functional reactivation.
Circulation Research.
122:31-46.
2018
Full text if available -
Tate MGrieve DJRitchie RH. Are targeted therapies for diabetic cardiomyopathy on the horizon?.
Clinical Science.
131:897-915.
2017
Full text if available -
Baltos J-AVecchio EAHarris MAQin CXRitchie RHChristopoulos AWhite PJMay LT. Capadenoson, a clinically trialed partial adenosine A 1 receptor agonist, can stimulate adenosine A 2B receptor biased agonism.
Biochemical Pharmacology.
135:79-89.
2017
Full text if available -
Qin CXFinlayson SBAl-Sharea ATate MDe Blasio MJDeo MRosli SPrakoso DThomas CJKiriazis HGould EYang YHMorand EFPerretti MMurphy AJDu X-JGao X-MRitchie RH. Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo.
Scientific Reports.
7:1-14.
2017
Full text if available -
Qin CXSleaby RDavidoff AJBell JRDe Blasio MJDelbridge LMChatham JCRitchie RH. Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications.
Pharmacological Research.
116:45-56.
2017
Full text if available -
Tate MDeo MCao AHHood SGHuynh KKiriazis HDu X-JJulius TLFigtree GADusting GJKaye DMRitchie RH. Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat.
Diabetes and Vascular Disease Research.
14:423-433.
2017
Full text if available -
Ritchie RHZerenturk EJPrakoso DCalkin AC. Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy.
Journal of Molecular Endocrinology.
58:R225-R240.
2017
Full text if available -
Chin KYQin CMay LRitchie RHWoodman OL. New pharmacological approaches to the prevention of myocardial ischemia-reperfusion injury.
Current Drug Targets.
18:1689-1711.
2017
Full text if available -
Prakoso DDe Blasio MJQin CRosli SKiriazis HQian HDu X-JWeeks KLGregorevic PMcMullen JRRitchie RH. Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction.
Clinical Science.
131:1345-1360.
2017
Full text if available -
Ng HHLeo CHPrakoso DQin CRitchie RHParry LJ. Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes.
Scientific Reports.
7.
2017
Full text if available -
Qin CXMay LTLi RCao NRosli SDeo MAlexander AEHorlock DBourke JEYang YHStewart AGKaye DMDu X-JSexton PMChristopoulos AGao X-MRitchie RH. Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice.
Nature Communications.
8.
2017
Full text if available -
Bubb KJKok CTang ORasko NBBirgisdottir ABHansen TRitchie RBhindi RReisman SAMeyer CWard KKarimi Galougahi KFigtree GA. The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling.
Free Radical Biology and Medicine.
108:585-594.
2017
Full text if available -
Sharma ARizky LStefanovic NTate MRitchie RHWard KWde Haan JB. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction.
Cardiovascular Diabetology.
16.
2017
Full text if available -
Ritchie RHDrummond GRSobey CGDe Silva TMKemp-Harper BK. The opposing roles of NO and oxidative stress in cardiovascular disease.
Pharmacological Research.
116:57-69.
2017
Full text if available -
De Blasio MJRamalingam ACao AHPrakoso DYe J-MPickering RWatson AMDde Haan JBKaye DMRitchie RH. The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy.
Behavioural Processes.
807:12-20.
2017
Full text if available -
Tare MKalidindi RSRBubb KJParkington HCBoon W-MLi XSobey CGDrummond GRRitchie RHKemp-Harper BK. Vasoactive actions of nitroxyl (HNO) are preserved in resistance arteries in diabetes.
Naunyn-Schmiedebergs Archives of Pharmacology.
390:397-408.
2017
Full text if available -
Kahlberg NQin CXAnthonisz JJap ENg HHJelinic MParry LJKemp-Harper BKRitchie RHLeo CH. Adverse vascular remodelling is more sensitive than endothelial dysfunction to hyperglycaemia in diabetic rat mesenteric arteries.
Pharmacological Research.
111:325-335.
2016
Full text if available -
Delbridge LMDBenson VLRitchie RHMellor KM. Diabetic Cardiomyopathy: The Case for a Role of Fructose in Disease Etiology.
Diabetes.
65:3521-3528.
2016
Full text if available -
Chin KYMichel LQin CXCao NWoodman OLRitchie RH. The HNO donor Angeli’s salt offers potential haemodynamic advantages over NO or dobutamine in ischaemia–reperfusion injury in the rat heart ex vivo.
Pharmacological Research.
104:165-175.
2016
Full text if available -
Kemp-Harper BKHorowitz JDRitchie RH. Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure.
Drugs.
76:1337-1348.
2016
Full text if available -
De Blasio MJHuynh KQin CRosli SKiriazis HAyer ACemerlang NStocker RDu X-JMcMullen JRRitchie RH. Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110α) signaling.
Free Radical Biology and Medicine.
87:137-147.
2015
Full text if available -
Qin CYang YHMay LGao XStewart AGTu YWoodman OLRitchie RH. Cardioprotective potential of annexin-A1 mimetics in myocardial infarction.
Pharmacology and Therapeutics.
148:47-65.
2015
Full text if available -
Cao NWong YGRosli SKiriazis HHuynh KQin CDu X-JKemp-Harper BKRitchie RH. Chronic Administration of the Nitroxyl Donor 1-Nitrosocyclo Hexyl Acetate Limits Left Ventricular Diastolic Dysfunction in a Mouse Model of Diabetes Mellitus In Vivo.
Circulation: Heart Failure.
8:572-581.
2015
Full text if available -
Bowden MATesch GHJulius TLRosli SLove JERitchie RH. Earlier onset of diabesity-Induced adverse cardiac remodeling in female compared to male mice.
Obesity.
23:1166-1177.
2015
Full text if available -
Huynh KBernardo BCMcMullen JRRitchie RH. Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways.
Pharmacology and Therapeutics.
142:375-415.
2014
Full text if available -
Chin KYQin CCao NKemp-Harper BKWoodman OLRitchie RH. The concomitant coronary vasodilator and positive inotropic actions of the nitroxyl donor Angeli's salt in the intact rat heart: contribution of soluble guanylyl cyclase-dependent and -independent mechanisms.
British Journal of Pharmacology.
171:1722-1734.
2014
Full text if available -
Fender ACPavic GDrummond GRDusting GJRitchie RH. Unexpected anti-hypertrophic responses to low-level stimulation of protease-activated receptors in adult rat cardiomyocytes.
Naunyn-Schmiedebergs Archives of Pharmacology.
387:1001-1007.
2014
Full text if available -
Joshi MSBerger PJKaye DMPearson JTBauer JARitchie RH. Functional relevance of genetic variations of endothelial nitric oxide synthase and vascular endothelial growth factor in diabetic coronary microvessel dysfunction.
Clinical and Experimental Pharmacology and Physiology.
40:253-261.
2013
Full text if available -
Irvine JCCao NGossain SAlexander AELove JEQin CHorowitz JDKemp-Harper BKRitchie RH. HNO/cGMP-dependent antihypertrophic actions of isopropylamine-NONOate in neonatal rat cardiomyocytes: potential therapeutic advantages of HNO over NO˙.
American Journal of Physiology: Heart and Circulatory Physiology.
305:H365-H377.
2013
Full text if available -
Ritchie RHLeo CHQin CStephenson EJBowden MABuxton KDLessard SJRivas DAKoch LGBritton SLHawley JAWoodman OL. Low intrinsic exercise capacity in rats predisposes to age-dependent cardiac remodeling independent of macrovascular function.
American Journal of Physiology: Heart and Circulatory Physiology.
304:H729-H739.
2013
Full text if available -
Mellor KMBell JRRitchie RHDelbridge LMD. Myocardial insulin resistance, metabolic stress and autophagy in diabetes.
Clinical and Experimental Pharmacology and Physiology.
40:56-61.
2013
Full text if available -
Qin CBuxton KDPepe SCao AHVenardos KLove JEKaye DMYang YHMorand EFRitchie RH. Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-A1 and its N-terminal-derived peptide Ac-ANX-A12-26.
British Journal of Pharmacology.
168:238-252.
2013
Full text if available -
Huynh KKiriazis HDu X-JLove JEGray SPJandeleit-Dahm KAMcMullen JRRitchie RH. Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice.
Free Radical Biology and Medicine.
60:307-317.
2013
Full text if available -
Dautov RFNgo DTMLicari GLiu SSverdlov ALRitchie RHKemp-Harper BKHorowitz JDChirkov YY. The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness.
Nitric Oxide: Biology and Chemistry.
35:72-78.
2013
Full text if available -
Ritchie RHLove JEHuynh KBernardo BCHenstridge DCKiriazis HTham YKSapra GQin CCemerlang NBoey EJHJandeleit-Dahm KDu X-JMcMullen JR. Enhanced phosphoinositide 3-kinase(p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes.
Diabetologia.
55:3369-3381.
2012
Full text if available -
Irvine JCGanthavee VLove JEAlexander AEHorowitz JDStasch J-PKemp-Harper BKRitchie RH. The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy.
PLoS ONE.
7:e44481-e44481.
2012
Full text if available -
Huynh KKiriazis HDu X-JLove JEJandeleit-Dahm KAForbes JMMcMullen JRRitchie RH. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.
Diabetologia.
55:1544-1553.
2012
Full text if available -
Lin EQIrvine JCCao AHAlexander AELove JEPatel RMcMullen JRKaye DMKemp-Harper BKRitchie RH. Nitroxyl (HNO) Stimulates Soluble Guanylyl Cyclase to Suppress Cardiomyocyte Hypertrophy and Superoxide Generation.
PLoS ONE.
7:e34892-e34892.
2012
Full text if available -
Mellor KMWendt IRRitchie RHDelbridge LMD. Fructose diet treatment in mice induces fundamental disturbance of cardiomyocyte Ca2+ handling and myofilament responsiveness.
American Journal of Physiology: Heart and Circulatory Physiology.
302:H964-H972.
2012
Full text if available -
Sourris KCHarcourt BETang PHMorley ALHuynh KPenfold SACoughlan MTCooper MENguyen T-VRitchie RHForbes JM. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes.
Free Radical Biology and Medicine.
52:716-723.
2012
Full text if available -
Mellor KMBell JRWendt IRDavidoff AJRitchie RHDelbridge LMD. Fructose Modulates Cardiomyocyte Excitation-Contraction Coupling and Ca2+ Handling In Vitro.
PLoS ONE.
6:e25204-e25204.
2011
Full text if available -
Mellor KMBell JRYoung MJRitchie RHDelbridge LMD. Myocardial autophagy activation and suppressed survival signaling is associated with insulin resistance in fructose-fed mice.
Journal of Molecular and Cellular Cardiology.
50:1035-1043.
2011
Full text if available -
Sverdlov ALNgo DTMNightingale AKRajendran SMishra KHeresztyn TRitchie RHMarwick THFrenneaux MPHorowitz JD. The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload.
Nitric Oxide: Biology and Chemistry.
25:41-46.
2011
Full text if available -
Smith NJChan H-WQian HBourne AMHannan KMWarner FJRitchie RHPearson RBHannan RDThomas WG. Determination of the Exact Molecular Requirements for Type 1 Angiotensin Receptor Epidermal Growth Factor Receptor Transactivation and Cardiomyocyte Hypertrophy.
Hypertension.
57:973-980.
2011
Full text if available -
Xu QDalic AFang LKiriazis HRitchie RHSim KGao X-MDrummond GSarwar MZhang Y-YDart AMDu X-J. Myocardial oxidative stress contributes to transgenic beta(2)-adrenoceptor activation-induced cardiomyopathy and heart failure.
British Journal of Pharmacology.
162:1012-1028.
2011
Full text if available -
Bullen MLMiller AAAndrews KLIrvine JCRitchie RHSobey CGKemp-Harper BK. Nitroxyl (HNO) as a vasoprotective signaling molecule.
Antioxidants and Redox Signaling.
14:1675-1686.
2011
Full text if available -
Mellor KRitchie RHMeredith GWoodman OLMorris MJDelbridge LMD. High-fructose diet elevates myocardial superoxide generation in mice in the absence of cardiac hypertrophy.
Nutrition.
26:842-848.
2010
Full text if available -
Huynh KMcMullen JRJulius TLTan JWLove JECemerlang NKiriazis HDu XJRitchie RH. Cardiac-Specific IGF-1 Receptor Transgenic Expression Protects Against Cardiac Fibrosis and Diastolic Dysfunction in a Mouse Model of Diabetic Cardiomyopathy.
Diabetes.
59:1512-1520.
2010
Full text if available -
Mellor KMRitchie RHDavidoff AJDelbridge LMD. Elevated dietary sugar and the heart: experimental models and myocardial remodeling.
Canadian Journal of Physiology and Pharmacology.
88:525-540.
2010
Full text if available -
Mellor KMRitchie RHDelbridge LMD. Reactive oxygen species and insulin-resistant cardiomyopathy.
Clinical and Experimental Pharmacology and Physiology.
37:222-228.
2010
Full text if available -
Ritchie RHIrvine JCRosenkranz ACPatel RWendt IRHorowitz JDKemp-Harper BK. Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond.
Pharmacology and Therapeutics.
124:279-300.
2009
Full text if available -
Ritchie RRosenkranz AKaye D. B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target.
Current Molecular Medicine.
9:814-825.
2009
Full text if available -
Venardos KMZatta AJMarshall TRitchie RKaye DM. Reduced L-arginine transport contributes to the pathogenesis of myocardial ischemia-reperfusion injury.
Journal of Cellular Biochemistry.
108:156-168.
2009
Full text if available -
Porrello ERBell JRSchertzer JDCurl CLMcMullen JRMellor KMRitchie RHLynch GSHarrap SBThomas WGDelbridge LMD. Heritable pathologic cardiac hypertrophy in adulthood is preceded by neonatal cardiac growth restriction.
American Journal of Physiology: Regulatory, Integrative and Comparative Physiology.
296:R672-R680.
2009
Full text if available -
Irvine JCRitchie RHFavaloro JLAndrews KLWiddop REKemp-Harper BK. Nitroxyl (HNO): the Cinderella of the nitric oxide story.
Trends in Pharmacological Sciences.
29:601-608.
2008
Full text if available -
Woodman OLMalakul WCao AHXu QRitchie RH. Atrial natriuretic peptide prevents diabetes-induced endothelial dysfunction.
Life Sciences.
82:847-854.
2008
Full text if available -
Ritchie RHQuinn JMCao AHDrummond GRKaye DMFavaloro JMProietto JDelbridge LMD. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo.
Journal of Molecular and Cellular Cardiology.
42:1119-1128.
2007
Full text if available -
Goh SSCWoodman OLPepe SCao AHQin CRitchie RH. The Red Wine Antioxidant Resveratrol Prevents Cardiomyocyte Injury Following Ischemia-Reperfusion Via Multiple Sites and Mechanisms.
Antioxidants and Redox Signaling.
9:101-113.
2007
Full text if available -
LASKOWSKI AWOODMAN OCAO ADRUMMOND GMARSHALL TKAYE DRITCHIE R. Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes.
Cardiovascular Research.
72:112-123.
2006
Full text if available -
Ritchie RHZeitz CJWuttke RDHii JTYHorowitz JD. Attenuation of the Negative Inotropic Effects of Metoprolol at Short Cycle Lengths in Humans.
Journal of the American College of Cardiology.
48:1234-1241.
2006
Full text if available -
Garreffa AMWoodman OLCao AHRitchie RH. Sodium Nitroprusside Protects Adult Rat Cardiac Myocytes From Cellular Injury Induced by Simulated Ischemia.
Journal of Cardiovascular Pharmacology.
47:1-8.
2006
Full text if available -
Ritchie RHGordon JMWoodman OLCao AHDusting GJ. Annexin-1 peptide Anx-12-26 protects adult rat cardiac myocytes from cellular injury induced by simulated ischaemia.
British Journal of Pharmacology.
145:495-502.
2005
Full text if available -
Ritchie RHRosenkranz ACHuynh LPStephenson TKaye DMDusting GJ. Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling.
American Journal of Physiology: Heart and Circulatory Physiology.
287:H1179-H1185.
2004
Full text if available -
Rosenkranz ACHood SGWoods RLDusting GJRitchie RH. B-Type Natriuretic Peptide Prevents Acute Hypertrophic Responses in the Diabetic Rat Heart: Importance of Cyclic GMP.
Diabetes.
52:2389-2395.
2003
Full text if available -
Candido RForbes JMThomas MCThallas VDean RGBurns WCTikellis CRitchie RHTwigg SMCooper MEBurrell LM. A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural Changes.
Circulation Research.
92:785-792.
2003
Full text if available -
Ritchie RRosenkranz A. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP.
Cardiovascular Research.
57:515-522.
2003
Full text if available -
Ritchie RHSun XBilszta JLGulluyan LMDusting GJ. Cardioprotective actions of an N-terminal fragment of annexin-1 in rat myocardium in vitro.
Behavioural Processes.
461:171-179.
2003
Full text if available -
Gordon JMDusting GJWoodman OLRitchie RH. Cardioprotective action of CRF peptide urocortin against simulated ischemia in adult rat cardiomyocytes.
American Journal of Physiology: Heart and Circulatory Physiology.
284:H330-H336.
2003
Full text if available -
Rosenkranz ACHood SGWoods RLDusting GJRitchie RH. Acute Antihypertrophic Actions of Bradykinin in the Rat Heart.
Hypertension.
40:498-503.
2002
Full text if available -
Rosenkranz ACDusting GJRitchie RH. Endothelial Dysfunction Limits the Antihypertrophic Action of Bradykinin in Rat Cardiomyocytes.
Journal of Molecular and Cellular Cardiology.
32:1119-1126.
2000
Full text if available -
Zeitz CJRitchie RHJarrett RGHii JTYWuttke RDHorowitz JD. The Positive Inotropic Effects of Milrinone But Not of Digoxin are Attenuated at Short Cycle Lengths.
Journal of Cardiovascular Pharmacology.
35:427-433.
2000
Full text if available -
Ritchie RHMarsh JDSchiebinger RJ. Bradykinin-stimulated protein synthesis by myocytes is dependent on the MAP kinase pathway and p70S6K.
American Journal of Physiology: Heart and Circulatory Physiology.
276:H1393-H1398.
1999
Full text if available -
Ritchie RHMarsh JDSchiebinger RJ. Bradykinin-stimulated protein synthesis by myocytes is dependent on the MAP kinase pathway and p70(S6K).
American Journal of Physiology: Heart and Circulatory Physiology.
276:H1393-H1398.
1999
-
Ritchie RHSchiebinger RJLapointe MCMarsh JD. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide.
American Journal of Physiology: Heart and Circulatory Physiology.
275:H1370-H1374.
1998
Full text if available -
Ritchie RHorowitz RHRAJD. ELIMINATION, BUT NOT ACCUMULATION, OF METOPROLOL BY RAT ISOLATED PERFUSED HEART IS SELECTIVELY IMPAIRED BY HYPOXIA.
Clinical and Experimental Pharmacology and Physiology.
25:548-551.
1998
Full text if available -
Marsh JDLehmann MHRitchie RHGwathmey JKGreen GESchiebinger RJ. Androgen Receptors Mediate Hypertrophy in Cardiac Myocytes.
Circulation.
98:256-261.
1998
Full text if available -
Ritchie RHHii JTYHorowitz JD. Relationship Between Myocardial Milrinone Content and Its Acute Hemodynamic and Electrophysiologic Effects.
Journal of Cardiovascular Pharmacology.
31:885-893.
1998
Full text if available -
Ritchie RHSallustio BCHii JTYHorowitz JD. Short-Term Myocardial Uptake of d- and l-Sotalol in Humans: Relation to Hemodynamic and Electrophysiologic Effects.
Journal of Cardiovascular Pharmacology.
31:876-884.
1998
Full text if available -
Ritchie RHMorgan DJHorowitz JD. Myocardial Effect Compartment Modeling of Metoprolol and Sotalol: Importance of Myocardial Subsite Drug Concentration.
Journal of Pharmaceutical Sciences.
87:177-182.
1998
Full text if available -
Ritchie RHMarsh JDLancaster WDDiglio CASchiebinger RJ. Bradykinin Blocks Angiotensin II–Induced Hypertrophy in the Presence of Endothelial Cells.
Hypertension.
31:39-44.
1998
Full text if available -
Ritchie RHWuttke RDHii JTYJarrett RGCarey ALHorowitz JD. The force-interval relationship of the left ventricle: A quantitative description in patients with ischemic heart disease.
Journal of Cardiac Failure.
1:273-284.
1995
Full text if available -
Zhang YIRitchie RHHorowitz JD. Postextrasystolic potentiation in patients with ischaemic heart disease: influence of inotropic agents..
British Journal of Clinical Pharmacology.
40:25-30.
1995
Full text if available -
Ritchie RHWuttke RDStafford IHorowitz JD. Relation Between Acute Myocardial Uptake and Hemodynamic and Electrocardiograpic Effects of Metoprolol in Humans.
Journal of Cardiovascular Pharmacology.
23:57-57.
1994
Full text if available
-
Tate MHiggins GCDe Blasio MJLindblom RPrakoso DDeo MKiriazis HPark MBaeza-Garza CDCaldwell STHartley RCKrieg TMurphy MPCoughlan MTRitchie RH. Correction to: The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart.
Cardiovascular Drugs and Therapy.
34:223-223.
2020
-
conference paper
-
Jelinic MLeo CHJackson KLDeo MParry LJRitchie RHQin CHead G. A6507 Renal fibrosis and vascular dysfunction in BPH/2J genetically hypertensive mice.
Journal of Hypertension.
e46-e46.
2018
Full text if available -
Tate MWillis AMDeo MDe Blasio MJPrakoso DKiriazis HDu X-JQian H-WMcGee SGregorevic PRitchie RH. Cardiac-selective targeting of histone deacetylase 4 to limit experimental diabetic cardiomyopathy.
European Heart Journal.
593-593.
2018
-
Prakoso DKiriazis HTate MQian HDeo MParry LGregorevic PDu XChatham JDe Blasio MRitchie R. Manipulation of cardiac O-GlcNAc modification alters cardiac function and remodelling in the setting of diabetic cardiomyopathy.
European Heart Journal.
1077-1078.
2018
-
Ramalingam ABudin SBMohd Fauzi NRitchie RHZainalabidin S. Mitochondria-Targeted Superoxide Scavenger Circumvents Nicotine-Induced Ventricular Dysfunction.
International Journal of Cardiology.
S4-S5.
2017
Full text if available -
Tate MOseghale ODe Blasio MJPrakoso DQian HKiriazis HDu XJGregorevic PRitchie RH. Cardiac-selective bone morphogenetic protein 7 (BMP7) gene therapy to target cardiac fibrosis in a mouse model of diabetic cardiomyopathy.
European Heart Journal.
932-932.
2017
-
Xue Qin CAnthonisz JKahlberg NHuei Leo CJap EParry LJHorowitz JKemp-Harper BKRitchie R. Approaches for Overcoming Diabetes-Induced Cardiovascular Nitric Oxide Resistance.
Free Radical Biology and Medicine.
S150-S151.
2016
Full text if available -
Ritchie R. INFLAMMATION AS A THERAPEUTIC TARGET IN CARDIOVASCULAR DISEASE.
Cardiology: international journal of cardiovascular medicine, surgery and pathology.
32-32.
2015
-
Qin CS Sleaby RSDelbridge LMDavidoff AJChatham JCRitchie RH. Acute Inhibition Of O-GlcNAc Signaling Rescues Inotropic Responsiveness In Type 1 Diabetic Rat Hearts.
Circulation Research.
2014
-
Qin CXCao NGao XMRosli SKiriazis HDu XJRitchie RH. ANNEXIN-A1 (ANX-A1) MIMETICS ATTENUATE ISCHEMIA REPERFUSION INJURY (I-R) IN THE INTACT HEART.
Clinical and Experimental Pharmacology and Physiology.
9-10.
2013
-
Ritchie R. Understanding the mechanisms of diabetic cardiomyopathy and its counter-regulation.
Cardiology: international journal of cardiovascular medicine, surgery and pathology.
28-28.
2013
-
Ritchie RHLeo CHQin CStephenson EJBowden MABuxton KDLessard SJRivas DAKoch LGBritton SLHawley JAWoodman OL. Impaired Intrinsic Exercise Capacity Predisposes to Progressive Left Ventricular Remodeling: Role of Mierovascular Endothelial Dysfunction and Impaired Glucose Utilization.
Circulation.
2012
-
Ritchie RHIrvine JCGanthavee VLove JEAlexander AEHorowitz JDStasch J-PKemp-Harper BK. The Soluble Guanylyl Cyclase (sGC) Activator BAY 58-2667 Selectively Limits Cardiomyocyte Hypertrophy - A Potential Therapeutic Advantage for Managing Left Ventricular Hypertrophy (LVH).
Circulation.
2012
-
Huynh KKiriazis HDu X-JLove JEJandeleit-Dahm KMcMullen JRRitchie RH. Coenzyme Q(10) Protects Against Diabetes-Induced Diastolic Dysfunction and Adverse Cardiac Remodeling in a Mouse Model of Type 1 Diabetes.
Circulation Research.
2012
-
Ritchie RHChin KYQin CCao NKemp-Harper BKWoodman OL. The Nitroxyl Donor Angeli's Salt Elicits Concomitant Concentration-Dependent Coronary Vasodilatory and Inotropic Actions in the Intact Rat Heart.
Circulation Research.
2012
-
Ritchie RHKhammy MMBowden MAIrvine JCAndrews KLHuynh KKiriazis HKaye DMVenardos K. Endothelial cationic amino acid transporter 1 (CAT-1) overexpression protects against diabetes-induced left ventricular (LV) dysfunction in mice.
European Heart Journal.
1097-1097.
2011
-
Huynh KBowden MAKiriazis HDu X-JJandeleit-Dahm KAForbes JMcMullen JRRitchie RH. Coenzyme Q(10) Rescues Diastolic Dysfunction, Cardiomyocyte Hypertrophy and Cardiac Fibrosis in Female db/db Type 2 Diabetic Mice.
Circulation.
2010
-
Ritchie RHLove JEKiriazis HHuynh KCemerlang NJulius TLJandeleit-Dahm KADu X-JMcMullen JR. Phosphoinositide 3-Kinase p110alpha (PI3Kalpha) Protects Against Diabetes-Induced Cardiac Superoxide Upregulation and Diastolic Dysfunction in a Mouse Model of Diabetic Cardiomyopathy.
Circulation.
2010
-
Sverdlov ALNgo DTNightingale AKRajendran SRitchie RHMarwick THFrenneaux MPHorowitz JD. Relationship between LV mass and diastolic function is independent of NO generation.
European Heart Journal.
121-121.
2010
-
Ritchie RHJulius TLBowden MATesch GH. Absence of Female Protection in the Development of Progressive Cardiac Remodeling in db/db Type 2 Diabetic Mice.
Circulation.
S866-S866.
2009
-
Huynh KJulius TLTan JKiriazis HMcMullen JRRitchie RH. Cardiac-Specific IGF-1 Receptor (IGF-1R) Transgenic Mice Are Protected Against Cardiac Fibrosis and Diastolic Dysfunction in Type 1 Diabetic Cardiomyopathy.
Circulation.
S789-S789.
2009
-
Huynh KJulius TLTan JWKiriazis HMcMullen JRRitchie RH. CARDIAC INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) RECEPTOR OVEREXPRESSION PREVENTS DIABETES-INDUCED CARDIAC FIBROSIS AND PRESERVES DIASTOLIC FUNCTION.
Hypertension.
1109-1109.
2009
-
Mellor KMRitchie RHDelbridge LMD. DIETARY FRUCTOSE-INDUCED CARDIAC HYPERTROPHY AND OXIDATIVE STRESS IS ASSOCIATED WITH SUPPRESSED MYOCARDIAL SIGNALLING THROUGH AKT.
Hypertension.
1112-1113.
2009
-
Miller AABullen MRavi RRitchie RHSobey CGKemp-Harper BK. NITROXYL (HNO) SERVES AS AN ANTIOXIDANT IN THE CEREBRAL VASCULATURE.
Hypertension.
1110-1110.
2009
-
Irvine JCGossain SLove JEKaye DMKemp-Harper BKRitchie RH. THE PROTECTIVE ROLE OF NITROXYL (HNO) AGAINST CARDIOMYOCYTE HYPERTROPHY VIA cGMP SIGNALLING.
Hypertension.
1109-1109.
2009
-
Ravi RMMiller AABullen MRitchie RHSobey CGKemp-Harper BK. Nitroxyl (HNO) exerts antioxidant actions in carotid arteries of mice.
The FASEB Journal.
2009
-
Ritchie RH. Evidence for a Causal Role of Oxidative Stress in the Myocardial Complications of Insulin Resistance.
Heart Lung and Circulation.
11-18.
2009
Full text if available -
Patel RRitchie RHWendt IR. Phenylephrine induced hypertrophy in neonatal cardiac myocytes is modulated by testosterone.
Journal of Molecular and Cellular Cardiology.
S138-S138.
2007
Full text if available -
Patel RRitchie RHCurl CLDelbridge LMWendt IR. Testosterone modulates physiological cardiac hypertrophy.
Journal of Molecular and Cellular Cardiology.
S139-S139.
2007
Full text if available -
Ritchie RLin ECao AKemp-Harper B. Novel prevention of cardiomyocyte hypertrophy by the nitroxyl anion via antioxidant actions.
Journal of Molecular and Cellular Cardiology.
745-745.
2006
Full text if available -
Patel RRitchie RHCurl CLDelbridge LMWendt IR. Ovariectomy exacerbates the hypertrophic response in a mouse model of primary cardiac hypertrophy.
Journal of Molecular and Cellular Cardiology.
742-743.
2006
Full text if available -
Ritchie RHDelbridge LMD. CARDIAC HYPERTROPHY, SUBSTRATE UTILIZATION AND METABOLIC REMODELLING: CAUSE OR EFFECT?.
Clinical and Experimental Pharmacology and Physiology.
159-166.
2006
Full text if available -
Ritchie RHQuinn JMCao AHDrummond GRKaye DMProietto JDelbridge LM. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant Glut4-deficient mouse in vivo.
Circulation.
U302-U302.
2005
-
Ritchie RHGoh SSCPepe SCao AHQin CWoodman OL. Cardioprotective actions of resveratrol in ischaemia reperfusion injury.
Journal of Molecular and Cellular Cardiology.
571-571.
2005
-
Patel RRitchie RHWendt IR. Modulation of phenylephrine-induced hypertrophy in neonatal rat cardiac myocytes by 17 beta-estradiol.
The FASEB Journal.
A1598-A1598.
2005
-
Patel RRitchie RWendt I. Sex dependent differences in cardiac myocyte hypertrophy.
Journal of Molecular and Cellular Cardiology.
301-302.
2004
-
Quinu JMDelbridge LMProietto JRitchie RH. Cardioprotective actions of the antioxidant tempol in GLUT4-deficient mice.
Clinical and Experimental Pharmacology and Physiology.
A25-A25.
2004
-
Laskowski AWoodman OLRitchie RH. Inhibition of superoxide signalling contributes to the antihypertrophic action of atrial natriuretic peptide.
Clinical and Experimental Pharmacology and Physiology.
A16-A16.
2004
-
Ritchie RHGarreffa AMGordon JMWoodman OL. Sodium nitroprusside protects cardiomyocytes from simulated ischemia/reperfusion injury independently of cyclic GMP.
Circulation.
157-157.
2003
-
Gordon JMDusting GJWoodman OLRitchie RH. Dexamethasone pretreatment protects cardiomyocytes from simulated ischaemia/reperfusion injury - Role of lipocortin.
Clinical and Experimental Pharmacology and Physiology.
A34-A34.
2003
-
Dusting ARGRitchie R. HYPERGLYCAEMIA ABOLISHES THE ANTIHYPERTROPHIC EFFICACY OF BRADYKININ IN RAT VENTRICULAR MYOCYTES.
Clinical and Experimental Pharmacology and Physiology.
519-521.
1999
Full text if available -
Ritchie RHSun XDusting GJ. LIPOCORTIN-1 PRESERVES MYOCARDIAL RESPONSIVENESS TO beta-ADRENERGIC STIMULATION IN RAT PAPILLARY MUSCLE.
Clinical and Experimental Pharmacology and Physiology.
522-524.
1999
Full text if available -
Sun XLRitchie RHSmith MDusting GJ. Lipocortin-1 prevents depression of myocardial contractility in rat papillary muscle.
Circulation.
113-113.
1998
-
Zeitz CJRitchie RHJarrett RGHii JTYHorowitz JD. Mechanical restitution predicts response to tachycardia in humans.
Circulation.
760-760.
1998
-
Jelinic MLeo CHJackson KLDeo MParry LJRitchie RHQin CHead G. A6507 Renal fibrosis and vascular dysfunction in BPH/2J genetically hypertensive mice.
Journal of Hypertension.
e46-e46.
2018
-
erratum
-
Qin CXFinlayson SBAl-Sharea ATate MDe Blasio MJDeo MRosli SPrakoso DThomas CJKiriazis HGould EYang YHMorand EFPerretti MMurphy AJDu X-JGao X-MRitchie RH. Author Correction: Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo.
Scientific Reports.
7185.
2018
Full text if available
-
Qin CXFinlayson SBAl-Sharea ATate MDe Blasio MJDeo MRosli SPrakoso DThomas CJKiriazis HGould EYang YHMorand EFPerretti MMurphy AJDu X-JGao X-MRitchie RH. Author Correction: Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo.
Scientific Reports.
7185.
2018